Morysa (Memantine Hydrochloride)

Memantine hydrochloride, the active ingredient in Morysa, is a NMDA receptor antagonist presented as an oral dosage form for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adults. GNH USA supplies Morysa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantine hydrochloride is used in the management of neurodegenerative conditions that involve glutamate‑mediated excitotoxicity. - Alzheimer’s disease (moderate to severe): helps maintain cognitive function and daily living activities. - Behavioral symptoms of Alzheimer’s disease: may reduce agitation and aggression. - Functional decline in Alzheimer’s disease: may slow progression of daily functional loss.

Memantine is generally well tolerated, but a range of adverse reactions have been reported.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Headache: mild to moderate cranial pain. - Constipation: reduced bowel movements. - Confusion: transient disorientation or difficulty concentrating. - Fatigue: feeling unusually tired. - Hypertension: elevated blood pressure readings.

Serious or Rare Side Effects: - Seizures: convulsive episodes requiring immediate medical attention. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Stevens‑Johnson syndrome: severe skin blistering and detachment. - Hepatic dysfunction: abnormal liver enzyme elevations. - Cardiac arrhythmias: irregular heart rhythms. - Suicidal thoughts: emergence of suicidal ideation or behavior.

When prescribing memantine, clinicians should consider several safety factors. - Renal impairment: dose adjustment may be required in patients with reduced kidney function. - History of seizures: monitor closely for increased seizure activity. - Cardiovascular disease: use cautiously in patients with uncontrolled hypertension or arrhythmias. - Pregnancy: safety category unknown; avoid unless potential benefit justifies risk. - Concomitant medications: review all drugs for possible interactions before initiating therapy. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Memantine may interact with other medications that affect the central nervous system or NMDA pathways.

Major Interactions (Avoid): - Amantadine: combined use can increase neurotoxic risk. - Ketamine: additive NMDA antagonism may cause excessive CNS depression. - Other NMDA antagonists: heightened risk of dizziness, confusion, and sedation.

Moderate Interactions (Monitor Closely): - Anticholinergics: may diminish memantine’s cognitive benefits. - Diuretics: can raise plasma concentrations of memantine. - CNS depressants (e.g., benzodiazepines): may enhance dizziness and sedation.